👌Superb review of #SSc ILD by @sclerodermaUM #ACR21 👉EARLY/SUBCLINICAL is NOT Mild ILD 👉MMF 1st 👉TCZ in combination for progressive phenotype/progression 👉Nintedanib:start slow, uptitrate for GI tolerability 👉Early HSCT referral (early dcSSc, FVC&DLCO 45-80%, Normal🫀) https://t.co/MUOhc3PakH

Prof. Ami Shah: Patients with #scleroderma have an ⬆ risk of #cancer vs. general population 📌Data from 3 recent meta-analysis: Scleroderma pts have 1.4 to 1.8 fold increased risk of cancer @RheumNow #ACR21 https://t.co/4uQN6y3tIn

Dr. Ami Shah shares her approach to cancer screening in patients with #scleroderma👇 @RheumNow #ACR21 https://t.co/chmlGe4iyl

Who declines most with #scleroderma #ILD - early dcSSc, ⬆️CRP, ⬆️mRSS all w more ⤵️FVC. Results verified in SENSIS trial of SSc ILD where #nintedanib was superior to placebo abst#1846 #ACR21 @RheumNow https://t.co/eckUj0qwch

Dr Ami Shah - Scleroderma & Cancer: 🛑 ⬆️ risk of ca around the time of dx in SSc patients with RNA-pol-III (especially first 5 years after dx), anti-Th/To protective? 🛑Her approach for ca screening in newly diagnosed with SSc pts and red flags as below #ACR21 #ACRambassador https://t.co/2VcWn2UInm

What if a celebrity had #Scleroderma? Would that ⬆️attention & funding for this rare disease? See what Big Bird says @RheumNow #ACR21 ?affected #PetsofACR @RheumNow @scleroderma @SclerodermaCAN audio-13.m4a

#ACR21 Thieves: SLE and SSc with worsening cytopenia and hematuria despite treatment: Maria Powell - presents overlap case with PNH, responded to eculizumab @Rheumnow https://t.co/CGvHEMA3lI

Interesting thoughts from Dr. Distler re:nintedanib & MMF in SSc-ILD Agree we should look into MMF-nintedanib combo, but this graph makes me think MMF > NIN Why would that be? Unlike NIN, MMF pts were NOT randomized, which likely favors NIN for a few (speculative) reasons: https://t.co/ZHBD8x74PM

🔥Continued, More Clinically Meaningful data in #SSc #ILD from #Nintedanib in >52 wk SENSCIS & SENSCIS-ON(open-label ext)#ACR21 Dr Distler ✨MMF likely to stay 1st line, then Nintedanib ❓Is it time for MMF + Antifibrotic upfront?? Await SLS-III;Data so far seems supportive https://t.co/JWXMlsJgmc

#ACR21 Abs#1367. Scleroderma pts with absent contractility (AC) associated with diffuse cutaneous disease, cardiac involvement, more severe Raynaud's. ⭐️14/67 AC pts died during study (21%), none without AC ⭐️15/16 Ro52+ pts had AC (p=0.06) https://t.co/GAuOiV5ScC @Rheumnow

• https://bit.ly/3C8u5Ul

#ACR21 #pedsrheum juvenile localized scleroderma Polypositive profile 3 or more autos correlated with more severe skin score, more activity https://t.co/vVXV4jjLvG

✨Great Pearls when screening patients for clinically suspect #Scleroderma or #Juvenile #Dermatomyositis 📌 Don’t Stop Work Up at Negative ANA if strongly suspect SSc 📌 #Myositis Specific Antibodies have different phenotypes in kids than adults (MDA-5, TIF-1g, NXP-2) #ACR21 https://t.co/KrkkzA5bkV